The total return over the past 12 months is -56.57% vs. +16.94% for the S&P 500. So far it's up -31.70% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (56.57%) | (33.61%) | (21.00%) | (12.54%) | (23.61%) | (16.82%) |
| Total Return CAGR | (56.57%) | (33.61%) | (21.00%) | (12.54%) | (23.61%) | (16.82%) |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Oncolytics Biotech Inc. (ONCY)
| Year | Start price | End price | ONCY Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $0.87 | $0.60 | (31.70%) | +14.51% | (46.21%) |
| 2025 | $0.91 | $0.87 | (4.36%) | +17.72% | (22.08%) |
| 2024 | $1.35 | $0.91 | (32.31%) | +24.89% | (57.20%) |
| 2023 | $1.63 | $1.35 | (17.18%) | +26.19% | (43.37%) |
| 2022 | $1.39 | $1.63 | +17.27% | (18.17%) | +35.44% |
| 2021 | $2.38 | $1.39 | (41.60%) | +28.74% | (70.34%) |
| 2020 | $4.76 | $2.38 | (50.00%) | +18.37% | (68.37%) |
| 2019 | $1.81 | $4.76 | +162.98% | +31.22% | +131.76% |
| 2018 | $5.42 | $1.81 | (66.61%) | (4.56%) | (62.05%) |
| 2017 | $2.00 | $5.42 | +171.00% | +21.70% | +149.30% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
